Cargando…
Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method
Glycocholic acid (GCA) is a novel identified biomarker for hepatocellular carcinoma (HCC). However, clinical pathological study of GCA has not been extensive due to the limited availability of anti-GCA monoclonal antibodies (mAbs) and restricted detection methods. In the present study, using human G...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396208/ https://www.ncbi.nlm.nih.gov/pubmed/30867740 http://dx.doi.org/10.3892/ol.2019.9943 |
_version_ | 1783399222271279104 |
---|---|
author | Wu, Miao Zhai, Songhui Gao, Julia Wei, Dapeng Xue, Jianxin Zhou, Yuxi Li, Nan Hu, Lijuan |
author_facet | Wu, Miao Zhai, Songhui Gao, Julia Wei, Dapeng Xue, Jianxin Zhou, Yuxi Li, Nan Hu, Lijuan |
author_sort | Wu, Miao |
collection | PubMed |
description | Glycocholic acid (GCA) is a novel identified biomarker for hepatocellular carcinoma (HCC). However, clinical pathological study of GCA has not been extensive due to the limited availability of anti-GCA monoclonal antibodies (mAbs) and restricted detection methods. In the present study, using human GCA conjugated with bovine serum albumin as the immunogen to immunize BALB/c mice, a novel anti-GCA mAb was generated and characterized. The isotypes of heavy chain and light chain of anti-GCA mAb were examined to be IgG2a and κ, respectively, with a high affinity constant (2.6×10(8) mol/l). The anti-GCA mAb binds GCA with high specificity and sensitivity, and the 50% inhibitory rate was 77.09 ng/ml. The present study also established a rapid, sensitive and efficient indirect competitive ELISA analysis using this anti-GCA mAb to detect the level of GCA produced by different HCC cell lines. Therefore, the present study may successfully develop a novel method for early HCC diagnosis, and also provide insights for further research and treatment of HCC. |
format | Online Article Text |
id | pubmed-6396208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-63962082019-03-13 Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method Wu, Miao Zhai, Songhui Gao, Julia Wei, Dapeng Xue, Jianxin Zhou, Yuxi Li, Nan Hu, Lijuan Oncol Lett Articles Glycocholic acid (GCA) is a novel identified biomarker for hepatocellular carcinoma (HCC). However, clinical pathological study of GCA has not been extensive due to the limited availability of anti-GCA monoclonal antibodies (mAbs) and restricted detection methods. In the present study, using human GCA conjugated with bovine serum albumin as the immunogen to immunize BALB/c mice, a novel anti-GCA mAb was generated and characterized. The isotypes of heavy chain and light chain of anti-GCA mAb were examined to be IgG2a and κ, respectively, with a high affinity constant (2.6×10(8) mol/l). The anti-GCA mAb binds GCA with high specificity and sensitivity, and the 50% inhibitory rate was 77.09 ng/ml. The present study also established a rapid, sensitive and efficient indirect competitive ELISA analysis using this anti-GCA mAb to detect the level of GCA produced by different HCC cell lines. Therefore, the present study may successfully develop a novel method for early HCC diagnosis, and also provide insights for further research and treatment of HCC. D.A. Spandidos 2019-03 2019-01-17 /pmc/articles/PMC6396208/ /pubmed/30867740 http://dx.doi.org/10.3892/ol.2019.9943 Text en Copyright: © Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wu, Miao Zhai, Songhui Gao, Julia Wei, Dapeng Xue, Jianxin Zhou, Yuxi Li, Nan Hu, Lijuan Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title | Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title_full | Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title_fullStr | Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title_full_unstemmed | Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title_short | Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
title_sort | diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396208/ https://www.ncbi.nlm.nih.gov/pubmed/30867740 http://dx.doi.org/10.3892/ol.2019.9943 |
work_keys_str_mv | AT wumiao diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT zhaisonghui diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT gaojulia diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT weidapeng diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT xuejianxin diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT zhouyuxi diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT linan diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod AT hulijuan diagnosisofhepatocellularcarcinomausinganovelantiglycocholicacidmonoclonalantibodybasedmethod |